Hospira's Inflectra becomes Europe's first approved biosimilar monoclonal antibody

|By:, SA News Editor

Celltrion and Hospira (HSP) get final approval from the European Commission for Inflectra.

The rheumatoid arthritis treatment is a biosimilar of Johnson & Johnson (JNJ) and Merck's (MRK) Remicade ($2B in European sales last year).

The news marks a biotech milestone: It's Europe's first biosimilar monoclonal antibody therapy.

HSP will launch the drug "at the earliest opportunity taking into account any relevant patent protection." (PR)